DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs

  • STATUS
    Recruiting
  • participants needed
    500
  • sponsor
    Biocad
Updated on 27 June 2022

Summary

This study was designed to evaluate the efficacy and safety of Extimia (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with solid tumours receiving myelosuppressive therapy

Details
Condition Patients With Solid Tumours Who Receive Myelosupressive Therapy
Treatment Empegfilgrastim
Clinical Study IdentifierNCT04811443
SponsorBiocad
Last Modified on27 June 2022

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note